← Leaderboards
Steven L. Zeichner
Children'S Research Institute
$5,050,207
Attributed
$7,008,311
Total exposure
12
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2008–25$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,008,311 · 12
By mechanism
R01$3,594,545 · 2
R21$1,658,332 · 3
R33$1,355,955 · 1
R56$339,344 · 1
M01$60,135 · 5
Top collaborators
- Claire M Fraser-Liggett5 shared
- Jacques Ravel5 shared
Others in their field
Top investigators on “Production”
- Eric S Lander · Whitehead Institute For Biomedical Res$568,626,051
- Bambra Strokes · Ppd Development Lp$526,656,217
- Richard A Gibbs · Baylor College Of Medicine$521,766,399
- Tracy L Nolen · Research Triangle Institute$451,761,218
- Sonia M Thomas · Research Triangle Institute$451,761,218
- David Heimbrook · Leidos Biomedical Research, Inc.$332,994,970
Research focus
ProductionCellsDesignResponseMonitorFundingRrna GenesTechnologyGenesClinical TrialsFutureProgramsDoctor Of PhilosophyGastrointestinal Tract StructureMicrobialPrincipal InvestigatorCharacteristicsMicrobiomeBaseVaccinesImmunogenicityExhibitsEnvironmentLife
Grant awards (24)
Globally Appropriate Genome Reduced Killed Whole Bacterial HIV Vaccines$282,625
R01 · FY2025 · AI · contact PI
Globally Appropriate Genome Reduced Killed Whole Bacterial HIV Vaccines$565,250
R01 · FY2024 · AI · contact PI
Globally Appropriate Genome Reduced Killed Whole Bacterial HIV Vaccines$565,250
R01 · FY2023 · AI · contact PI
Pilot Study of Rectal Microbial Biomarkers for Appendicitis Diagnosis$207,125
R21 · FY2016 · DK · contact PI
Pilot Study of Rectal Microbial Biomarkers for Appendicitis Diagnosis$270,931
R21 · FY2015 · DK · contact PI
Identification of Antigens for Anti-HIV Broadly Neutralizing Responses$501,414
R01 · FY2013 · AI · contact PI
Development of an in vivo screening technology for cancer vaccine immunogens$230,155
R21 · FY2013 · CA · contact PI
Identification of Antigens for Anti-HIV Broadly Neutralizing Responses$541,762
R01 · FY2012 · AI · contact PI
HIV Microbicides and the Vaginal Microbiome$438,399
R33 · FY2012 · AI · contact PI
Development of an in vivo screening technology for cancer vaccine immunogens$244,923
R21 · FY2012 · CA · contact PI
Identification of Antigens for Anti-HIV Broadly Neutralizing Responses$552,901
R01 · FY2011 · AI · contact PI
HIV Microbicides and the Vaginal Microbiome$438,570
R33 · FY2011 · AI · contact PI
Development of an in vivo screening technology for cancer vaccine immunogens$227,310
R21 · FY2011 · CA · contact PI
Identification of Antigens for Anti-HIV Broadly Neutralizing Responses$585,343
R01 · FY2010 · AI · contact PI
HIV Microbicides and the Vaginal Microbiome$478,986
R33 · FY2010 · AI · contact PI
Metagenomic Evaluation of the Oral Flora of Pediatric HIV Patients$339,344
R56 · FY2010 · DE · contact PI
IMPAACT P1066: A PHASE I/II MULTICENTER, OPEN-LABEL, NONCOMPARATIVE STUDY OF$21,885
M01 · FY2010 · RR · contact PI
PACTG P1047 SAFETY AND IMMUNOGENICITY OF QUADRIVALENT HUMAN PAPILLOMA VIRUS$7,294
M01 · FY2010 · RR · contact PI
WIRB - AN OPEN-LABEL, MULTIPLE-DOSE, CROSS-OVER STUDY TO EVALUATE: HIV$3,126
M01 · FY2010 · RR · contact PI
HIV Microbicides and the Vaginal Microbiome$224,465
R21 · FY2009 · AI · contact PI
IMPAACT P1066: A PHASE I/II MULTICENTER, OPEN-LABEL, NONCOMPARATIVE STUDY OF$16,700
M01 · FY2009 · RR · contact PI
HIV Microbicides and the Vaginal Microbiome$13,347
R21 · FY2009 · AI · contact PI
PACTG P1047 SAFETY AND IMMUNOGENICITY OF QUADRIVALENT HUMAN PAPILLOMA VIRUS$11,130
M01 · FY2009 · RR · contact PI
HIV Microbicides and the Vaginal Microbiome$240,076
R21 · FY2008 · AI · contact PI